Tirzepatide and GIP/GLP-1 Receptor Agonists: Unlocking New Research Avenues
Tirzepatide represents a new class of drug in diabetes and metabolic disorder research, capitalizing on a dual-action mechanism through the simultaneous activation of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Traditionally, GLP-1 receptor agonists have been highly effective in managing Type 2 diabetes due to their role in glucose control, insulin production, and … Read more